Market closedNon-fractional
ADMA Biologics/ADMA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About ADMA Biologics
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Ticker
ADMA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Ramsey, United States
Employees
624
Website
www.admabiologics.com
ADMA Biologics Metrics
BasicAdvanced
$3B
Market cap
-
P/E ratio
-$0.02
EPS
0.43
Beta
-
Dividend rate
Price and volume
Market cap
$3B
Beta
0.43
Financial strength
Current ratio
5.207
Quick ratio
1.788
Long term debt to equity
91.3
Total debt to equity
92.011
Interest coverage (TTM)
2.08%
Management effectiveness
Return on assets (TTM)
8.51%
Return on equity (TTM)
-2.43%
Valuation
Price to revenue (TTM)
10.426
Price to book
19.71
Price to tangible book (TTM)
20.21
Price to free cash flow (TTM)
185.603
Growth
Revenue change (TTM)
55.68%
Earnings per share change (TTM)
-93.08%
3-year revenue growth (CAGR)
80.61%
3-year earnings per share growth (CAGR)
-72.49%
What the Analysts think about ADMA Biologics
Analyst Ratings
Majority rating from 4 analysts.
ADMA Biologics Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$82M
10.69%
Net income
$18M
-201.14%
Profit margin
21.76%
-191.39%
ADMA Biologics Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.03
$0.01
-$0.08
$0.08
-
Expected
-$0.03
-$0.01
$0.03
$0.06
$0.08
Surprise
20.00%
-233.33%
-420.00%
45.45%
-
ADMA Biologics News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for ADMA Biologics stock?
ADMA Biologics (ADMA) has a market cap of $3B as of July 27, 2024.
What is the P/E ratio for ADMA Biologics stock?
The price to earnings (P/E) ratio for ADMA Biologics (ADMA) stock is 0 as of July 27, 2024.
Does ADMA Biologics stock pay dividends?
No, ADMA Biologics (ADMA) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next ADMA Biologics dividend payment date?
ADMA Biologics (ADMA) stock does not pay dividends to its shareholders.
What is the beta indicator for ADMA Biologics?
ADMA Biologics (ADMA) has a beta rating of 0.43. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.
Buy or sell ADMA Biologics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.